Abstract
Between 15% and 30% of patients with renal cell carcinoma present with metastatic disease by the time of diagnosis and one quarter of patients treated with curative intent suffer from relapse of renal cell carcinoma at distant sites. In the last 25 years, there has been a tremendous evolution of therapeutic concepts starting with the use of cytokines, the introduction of targeted therapies, and most recently the renaissance of immunotherapies. Furthermore, established treatments like cytoreductive nephrectomy lost their status due to new and long-awaited trial results. We will give an overview of the most important past and current therapies and therapy strategies of metastatic renal cell carcinoma including the treatment of metastatic non-clear cell renal cell carcinoma.
| Original language | English |
|---|---|
| Title of host publication | Primer on Urology |
| Number of pages | 13 |
| Publisher | Springer Science + Business Media |
| Publication date | 01.01.2025 |
| Pages | 317-329 |
| ISBN (Print) | 9783031554049 |
| ISBN (Electronic) | 9783031554056 |
| DOIs | |
| Publication status | Published - 01.01.2025 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
DFG Research Classification Scheme
- 2.22-14 Hematology, Oncology
Fingerprint
Dive into the research topics of 'Renal Cell Carcinoma: Metastatic'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver